Interparfums, Inc. (IPAR)
(Delayed Data from NSDQ)
$121.69 USD
+0.62 (0.51%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $121.49 -0.20 (-0.16%) 7:58 PM ET
1-Strong Buy of 5 1
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$121.69 USD
+0.62 (0.51%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $121.49 -0.20 (-0.16%) 7:58 PM ET
1-Strong Buy of 5 1
D Value B Growth D Momentum C VGM
Zacks News
e.l.f. Beauty's (ELF) Naturium Buyout to Boost Skincare Lineup
by Zacks Equity Research
e.l.f. Beauty's (ELF) recent announcement of its $355 million acquisition of Naturium signals a strategic move that can substantially boost its presence in the skincare market.
The J.M. Smucker (SJM) Raises EPS Guidance on Q1 Earnings Beat
by Zacks Equity Research
The J.M. Smucker's (SJM) first-quarter fiscal 2024 results reflect gains from favorable volumes and positive net price realization. Management raises the fiscal 2024 bottom-line guidance.
Altria's (MO) Pricing & Smoke-Free Strength Aid Amid Hurdles
by Zacks Equity Research
Altria (MO) benefits from its smoke-free alternatives and pricing strength amid cost inflation and low cigarette volumes.
McCormick (MKC) Thrives on Strategic Buyouts & Efficiency Plans
by Zacks Equity Research
McCormick (MKC) benefits from its strategic acquisitions and innovative initiatives. Robust efficiency programs also aid amid cost inflation.
Philip Morris' (PM) Pricing, Smoke-Free Forte Aid Amid Hurdles
by Zacks Equity Research
Philip Morris (PM) benefits from its smoke-free alternatives and pricing strength amid cost inflation and low cigarette volumes.
Estee Lauder (EL) Q4 Earnings Beat Estimates, Sales Up Y/Y
by Zacks Equity Research
Estee Lauder's (EL) fourth-quarter fiscal 2023 results reflect strength in nearly all categories other than Skin Care. The company remains well-placed for fiscal 2024.
Zacks.com featured highlights include Inter Parfums, MercadoLibre, Modine Manufacturing, AMETEK and RLI
by Zacks Equity Research
Inter Parfums, MercadoLibre, Modine Manufacturing, AMETEK and RLI are part of the Zacks Screen of the Week article.
5 Best Stocks to Buy for Remarkable Earnings Growth
by Tirthankar Chakraborty
Invest in stocks like Inter Parfums (IPAR), MercadoLibre (MELI), Modine Manufacturing (MOD), AMETEK (AME) & RLI for solid earnings growth
Wall Street Analysts See a 26.33% Upside in Inter Parfums (IPAR): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Inter Parfums (IPAR) points to a 26.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Inter Parfums (IPAR) Ups '23 EPS Guidance on Q2 Earnings Beat
by Zacks Equity Research
Inter Parfums' (IPAR) second-quarter 2023 results reflect higher earnings and sales on growth across Europe and U.S.-based operations. Management raises the 2023 earnings view.
Inter Parfums (IPAR) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inter Parfums (IPAR) delivered earnings and revenue surprises of 22.47% and 0.05%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Inter Parfums (IPAR) Queued for Q2 Earnings: Things to Note
by Zacks Equity Research
Inter Parfums' (IPAR) second-quarter 2023 performance will likely reflect gains from the company's brand strength across U.S. and European operations.
Upstart (UPST) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Upstart's (UPST) second-quarter 2023 performance is likely to have benefited from recent additions to its product portfolio amid a challenging macro environment and tightening from funding partners.
Is a Surprise Coming for Inter Parfums (IPAR) This Earnings Season?
by Zacks Equity Research
Inter Parfums (IPAR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
3D Systems (DDD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
3D Systems' (DDD) second-quarter results are likely to reflect strong demand for healthcare products and stabilization in industrial division.
Factors Likely to Drive Purple Innovation's (PRPL) Q2 Earnings
by Zacks Equity Research
Purple Innovation's (PRPL) Q2 results are likely to reflect gains from the innovative product line and efforts to reduce costs amid inflationary pressures and a demand shift.
Medifast (MED) Queued for Q2 Earnings: Things to Consider
by Zacks Equity Research
Medifast's (MED) second-quarter 2023 performance will likely reflect challenges related to customer acquisition and higher cost inflation.
Nu Skin (NUS) Lowers 2023 Guidance Despite Q2 Earnings Beat
by Zacks Equity Research
Nu Skin (NUS) reports sequential improvements in Q2 results, driven by the Mainland China and Rhyz segments. However, macro-economic factors pose challenges in the key markets.
Is Vertiv Holdings (VRT) Likely to Surpass Q2 Earnings Estimates?
by Zacks Equity Research
Vertiv Holdings' (VRT) second-quarter performance is likely to have been aided by solid demand for its digital infrastructure and continuity solutions.
What's on the Cards for Monster Beverage (MNST) in Q2 Earnings?
by Zacks Equity Research
Monster Beverage's (MNST) Q2 results are expected to reflect gains from continued strength in the energy drinks category and robust product innovation plans.
Things You Need to Know Before Corteva's (CTVA) Q2 Earnings
by Zacks Equity Research
A favorable product mix and pricing gains are likely to have contributed to Corteva's (CVTA) Q2 performance. However, currency headwinds and higher input costs are likely to have ailed.
Cloudflare (NET) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Cloudflare's (NET) second-quarter performance is likely to have been aided by solid demand for security solutions and the benefits of its recurring subscription-based business model.
Fortinet (FTNT) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Fortinet's (FTNT) second-quarter 2023 earnings are likely to have been aided by the strong adoption of Security Fabric, cloud and SD-WAN offerings.
Procter & Gamble (PG) Rises on Q4 Earnings Beat, Robust View
by Zacks Equity Research
Procter & Gamble's (PG) Q4 results reflect strong gains from its pricing actions, robust demand, improved sales and margins, and a positive product mix.
Inter Parfums (IPAR) Ups 2023 Guidance on Robust Q2 Sales
by Zacks Equity Research
Inter Parfums' (IPAR) sales increase year over year in second-quarter 2023. Management raises its top-line view for 2023.